Matthew Kiernan, MBBS, PhD, DSc, FRACP, FAHMS, University of Sydney, Sydney, Australia, outlines the current landscape of treatment options for patients with amyotrophic lateral sclerosis (ALS). Currently, only two FDA-approved pharmacologic therapies are indicated for the treatment of ALS: riluzole and edaravone. Recently, it was announced that the FDA accepted the AMX0035 new drug application for priority review. Additionally, many clinical trials are underway, including a study on lithium therapy for ALS patients with the UNC13A variant and trials on antisense oligonucleotides therapy directed against mutant SOD1 and C9orf72 mutations. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.